NCT06376721 2024-04-19
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 1/2 Recruiting
Clinical Trials
11 trialsNCT03155425 2024-02-01
PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT05559008 2022-11-09
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
Ruijin Hospital
Phase 1/2 Unknown
NCT05320081 2022-04-11
Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma
Huazhong University of Science and Technology
Phase 2 Unknown
NCT04476459 2021-03-15
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Sun Yat-sen University
Phase 1/2 Unknown
NCT04510610 2020-08-12
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2/3 Unknown
NCT03363555 2020-06-18
SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04337606 2020-04-07
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT04239170 2020-01-23
Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma
Peking University
Phase 2 Unknown
NCT03250962 2019-04-01
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown
NCT03701022 2018-10-09
PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma
Peking University
Phase 2 Unknown